These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1097 related items for PubMed ID: 12527999

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ, Torjanski N, Burn DJ.
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
    Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F, 043 Study Group.
    J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE.
    Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
    [Abstract] [Full Text] [Related]

  • 9. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease.
    Brooks DJ, Abbott RJ, Lees AJ, Martignoni E, Philcox DV, Rascol O, Roos RA, Sagar HJ.
    Clin Neuropharmacol; 1998 Dec; 21(2):101-7. PubMed ID: 9579296
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH, Klasser M, Reichmann H.
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
    Tompson D, Oliver-Willwong R.
    Clin Neuropharmacol; 2009 Oct; 32(3):140-8. PubMed ID: 18978485
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B, Angersbach D, Jost WH.
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
    [Abstract] [Full Text] [Related]

  • 18. Ropinirole: new preparation. Wait for more convincing data.
    Prescrire Int; 1998 Apr; 7(34):36-8. PubMed ID: 10183378
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ropinirole therapy for Parkinson's disease.
    Pahwa R, Lyons KE, Hauser RA.
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.